Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10173771" target="_blank" >RIV/00179906:_____/13:10173771 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/13:43874875 RIV/00216208:11150/13:10173771
Result on the web
<a href="http://www.elis.sk/download_file.php?product_id=3680&session_id=r9hurqfala1jhhvpvfljb10ik3" target="_blank" >http://www.elis.sk/download_file.php?product_id=3680&session_id=r9hurqfala1jhhvpvfljb10ik3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/BLL_2013_149" target="_blank" >10.4149/BLL_2013_149</a>

Result language
angličtina
Original language name
Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia
Original language description
We evaluated acute and chronic cardiotoxicity of anthracyclines with plasma glycogen phosphorylase BB (GPBB) measured by ELISA. We found that acute leukemia patients treated with anthracycline-based chemotherapy have significantly higher plasma GPBB concentrations in comparison with healthy subjects and GPBB after treatment correlated with diastolic left ventricular dysfunction on echocardiography.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)